SCHEMBL3487706

SCHEMBL3487706

Cc1ccc(Oc2ccc(N)c(CNC(=O)O)c2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.41
PPARD Q03181 2/20 0.41
PPARA Q07869 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
CHRM4 P08173 2/20 0.39
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
FFAR4 Q5NUL3 2/20 0.38
GCK P35557 2/20 0.37
KMT2A Q03164 1/20 0.36
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
KLKB1 P03952 1/20 0.36
MTOR P42345 1/20 0.36
HTR2A P28223 1/20 0.36
SLC6A4 P31645 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487565 0.90 HTR2A (0.46) PPARGPPARDPPARACHRM4CARM1
SCHEMBL3488807 0.90 SLC1A3 (0.45) PPARGPPARDPPARACHRM4CARM1
SCHEMBL3488403 0.88 SMN1; SMN2 (0.42) PPARGPPARDPPARAKMT2AHTR2A
SCHEMBL3488032 0.86 SLC6A4 (0.45) PPARGPPARAHTR2ASLC6A4KCNH2
SCHEMBL3488332 0.85 GCK (0.46) PPARGPPARDPPARACARM1PRMT6
SCHEMBL3488269 0.84 EGLN1 (0.42) PPARGPPARDPPARAFFAR4GCK
SCHEMBL3487040 0.84 HTR2A (0.45) PPARGPPARDPPARACARM1PRMT6
SCHEMBL3488176 0.84 TEAD4 (0.46) FFAR4GCK
SCHEMBL3488035 0.84 ALDH1A1 (0.41)
SCHEMBL3487417 0.84 HTR2A (0.46) KMT2AHTR2ASLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA PPARG 1/4885PPARD 4/4885PPARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.